Download PDF
Thromb Haemost 1997; 78(01): 205-209
DOI: 10.1055/s-0038-1657527
Clinical trials with anti IIb/IIIa inhibitors in acute coronary syndromes
Schattauer GmbH Stuttgart

Platelet Glycoprotein IIb/IIIa Integrin Blockade: Recent Clinical Trials in Interventional Cardiology

James E Tcheng
Department of Medicine, Duke University Medical Center, Durham, NC, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-168
    CrossrefPubMedGoogle Scholar
  • 2 Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719
    CrossrefPubMedGoogle Scholar
  • 3 Bamathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld Jr JW. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125-134
    CrossrefPubMedGoogle Scholar
  • 4 Lembo NJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas Jr JS, King SB. 3d Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65: 422-426
    CrossrefPubMedGoogle Scholar
  • 5 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein Db/DIa complex. J Clin Invest 1985; 76: 101-108
    CrossrefPubMedGoogle Scholar
  • 6 Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. eds The Heart and Cardiovascular System. Raven Press; New York, NY: 1992. pp 219-273
    Google Scholar
  • 7 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein Db-DIa complex. Blood 1988; 71: 831-843
    PubMedGoogle Scholar
  • 8 Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549-554
    CrossrefPubMedGoogle Scholar
  • 9 Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein Db/IIIa: member of a family of Arg-Gly-Asp—specific adhesion receptors. Science 1986; 231: 1559-1562
    CrossrefPubMedGoogle Scholar
  • 10 Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein nb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17 (6 Suppl B) 89B-95B
    PubMedGoogle Scholar
  • 11 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein Ilb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559
    CrossrefPubMedGoogle Scholar
  • 12 Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 127-181
    PubMedGoogle Scholar
  • 13 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein Ilb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764
    CrossrefPubMedGoogle Scholar
  • 14 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-961
    CrossrefPubMedGoogle Scholar
  • 15 Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G. et al Bleeding complications with the chimeric antibody to platelet glycoprotein Ilb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995; 91: 2882-2890
    CrossrefPubMedGoogle Scholar
  • 16 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M. etal Randomised trial of coronary intervention with antibody against platelet lib/ Ilia integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881-886
    CrossrefPubMedGoogle Scholar
  • 17 Simoons ML, de BoerMJ, van der, Brand MJBM. et al Randomized trial of a GP Ilb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603
    CrossrefPubMedGoogle Scholar
  • 18 Simoons ML. et al The Capture Study, Lancet. 1997. in press.
    Google Scholar
  • 19 Lincoff AM. et al Results of the interim analysis of the EPILOG Trial. J Am Coll Cardiol 1996; 27 (suppl A) 21
    PubMedGoogle Scholar
  • 20 American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 0403-1406
    CrossrefPubMedGoogle Scholar
  • 21 Lincoff AM. et al Marked enhancement of clinical efficacy of platelet GP Db/DIa blockade with c7E3 Fab (abciximab) linked to reduction in bleeding complications: outcome in the EPILOG and EPIC trials. Circulation 1996; 94 (suppl) 001-375
    CrossrefPubMedGoogle Scholar
  • 22 IMPACT-II Investigators. Effects of Competitive Platelet Glycoprotein Db/DIa Inhibition with Velofibatide (Integrilin*) in Reducing Complications of Percutaneous Coronary Intervention: Results of the Randomized Clinical Trial IMPACT-II. Lancet. 1997. in press
    Google Scholar
  • 23 Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ. et al Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein Db/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995; 91: 2151-2157
    CrossrefPubMedGoogle Scholar
  • 24 Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D. et al Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein Db/IDa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-1227
    CrossrefPubMedGoogle Scholar
  • 25 King III SB. Administration of Tirofiban (MK-0383) will reduce the incidence of adverse cardiac outcome following PTCA/ DCA (RESTORE). J Am Coll Cardiol 1996; 27 (suppl A) 21
    PubMedGoogle Scholar
  • 26 Peerlinck K, De LepeleireI, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmy nH, Vermylen J, Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein Db/DIa antagonist, is active in man. Circulation 1993; 88: 1512-1517
    CrossrefPubMedGoogle Scholar
  • 27 Egbertson MS, Chang CT, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch Jr JJ, Lynch RJ, Manno PD. et al Non-peptide fibrinogen receptor antagonists 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994; 37: 2537-2551
    CrossrefPubMedGoogle Scholar